SEC Form 4 · accession 0001209191-16-103558
HCA Healthcare, Inc. · HCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravi S. Chari
Officer — SVP-Clinical Excellence
Period of report
Feb 25, 2016
Accepted (ET)
Feb 29, 2016 · 8:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000860730
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2016 | A | 264 | $0.00 | A | 9,475 | D | |
| Common Stock | Feb 25, 2016 | A | 562 | $0.00 | A | 10,037 | D | |
| Common Stock | Feb 25, 2016 | A | 500 | $0.00 | A | 10,537 | D | |
| Common Stock | Feb 25, 2016 | F | 364 | $70.00 | D | 10,173 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightF4 | $22.95 | Feb 25, 2016 | A | 2,500 | A | Feb 25, 2016 | Feb 8, 2022 | Common Stock | 2,500 | 2,500 | D |
| Stock Appreciation RightF5 | $37.18 | Feb 25, 2016 | A | 2,125 | A | Feb 25, 2016 | Feb 6, 2023 | Common Stock | 2,125 | 2,125 | D |
| Stock Appreciation RightF6 | $47.97 | Feb 25, 2016 | A | 1,750 | A | Feb 25, 2016 | Feb 5, 2024 | Common Stock | 1,750 | 1,750 | D |
| Restricted Stock UnitsF7,F8 | — | Feb 25, 2016 | A | 1,860 | A | — | — | Common Stock | 1,860 | 1,860 | D |
Explanation of responses
- F1On February 8, 2012, the reporting person was granted 1,050 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2012, 2013, 2014 and 2015 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the restricted stock units subject to such criteria vested, resulting in the vesting of 264 restricted stock units.
- F2On February 6, 2013, the reporting person was granted 2,250 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the restricted stock units subject to such criteria vested, resulting in the vesting of 562 restricted stock units.
- F3On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the restricted stock units subject to such criteria vested, resulting in the vesting of 500 restricted stock units.
- F4On February 8, 2012, the reporting person was granted 10,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2012, 2013, 2014 and 2015 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 2,500 stock appreciation rights.
- F5On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 2,125 stock appreciation rights.
- F6On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2015, 100% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,750 stock appreciation rights.
- F7Each restricted stock unit represents a contingent right to receive one share of HCA Holdings, Inc. common stock.
- F8The restricted share units vest in two equal installments on the second and third anniversaries of the grant date.